Search results

Filters

  • Journals
  • Autorzy
  • Keywords
  • Date
  • Typ

Search results

Number of results: 6
items per page: 25 50 75
Sort by:
Download PDF Download RIS Download Bibtex

Abstract

Organophosphate (OP) pesticides are commonly known for their neurotoxicity. In the current experiments, two OPs used agriculturally, chlorpyrifos and dimethoate, were separately adminis- tered with centrally acting caffeine that is known to affect the pharmacological action of other substances. The aim of this study was to determine whether the combination of OP and caffeine may influence their neurotoxic potential. For this purpose, some neurobehavioral effects of this concomitant exposure were assessed in adult Swiss mice. All substances were given intra- peritoneally (i.p.) as single injections. In the passive avoidance task, chlorpyrifos (100 mg/kg) administered together with caffeine (40 mg/kg) significantly impaired acquisition. In the rota-rod test, the addition of caffeine at doses of 20 and 40 mg/kg, induced motor coordination impairment in chlorpyrifos (100 mg/kg)-treated mice. Neurobehavioral impairments were not observed for caffeine, chlorpyrifos and dimethoate (50 mg/kg) given separately as well as for the combina- tion of dimethoate and caffeine. Chlorpyrifos (100 mg/kg) alone and in combination with caffeine (40 mg/kg) significantly reduced acetylcholinesterase (AChE) activity. The current study shows that concomitant exposure to caffeine and chlorpyrifos can cause neurotoxic effects in mice despite the absence of these effects when caffeine and chlorpyrifos are administered alone. How- ever, the possible mechanisms involved need further investigations.
Go to article

Authors and Affiliations

K. Łukawski
1 2
G. Raszewski
3
K. Kruszyński
1
S.J. Czuczwar
2

  1. Department of Physiopathology, Institute of Rural Health, Jaczewskiego 2, 20-090 Lublin, Poland
  2. Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8, 20-090 Lublin, Poland
  3. Department of Toxicology and Food Protection, Institute of Rural Health, Jaczewskiego 2, 20-090 Lublin, Poland
Download PDF Download RIS Download Bibtex

Abstract

The aim of our research was to investigate the genotoxic effects of cobalt chloride and copper chloride in mouse bone marrow cells using the micronucleus (MN) assay. The three different concentrations of cobalt chloride (11.2, 22.5 and 45 mg kg-1) and copper chloride (1.17, 2.35 and 4.70 mg kg-1) were injected intraperitoneally to mice for 24 and 48 hours. It was observed that both of these heavy metals induced a significant increase in frequency of micronucleated polychromatic erythrocytes (MNPCE) at different concentrations in mice for 24 and 48 hours when compared with the control. Furthermore, the significant reduction for the polychromatic erythrocyte/normochromatic erythrocyte (PCE/NCE) ratio which is indicative of bone marrow cytotoxicity was observed in bone marrow cells which were treated with copper chloride at all concentrations for 24 and 48 hours. No reduction of the PCE/NCE ratio was observed both 24 and 48 hours after all the doses of cobalt chloride tested as compared to the negative control. These results lead us to the conclusion that copper chloride may have genotoxic and cytotoxic properties due to induction in the frequency of MN and a reduction in PCE/NCE ratio in bone marrow cells of mice, whereas cobalt chloride induced only genotoxic effect in mice bone marrow

Go to article

Authors and Affiliations

Pinar Goc Rasgele
Meral Kekecoglu
Fulya Dilek Gokalp Muranli
Download PDF Download RIS Download Bibtex

Abstract

Current study was designed to investigate the protective effects of royal jelly on Flunixin me- glumine (FM)-induced spermiotoxicity related to sperm concentration, abnormal spermatozoa count and histopathological changes in mice testis. The subjects were divided into five groups according to FM and/or royal jelly intake: Control group; group 1, FM alone (25 mg/kg, im); group 2, combination of FM (25 mg/kg, im) and royal jelly (200 mg/kg, oral); group 3, FM alone (50 mg/kg, im); and group 4, combination of FM (50 mg/kg, im) and royal jelly (200 mg/kg, oral). The animals were fed once daily for 15 days and they were sacrificed last day. Epididymal sperm concentration and abnormal spermatozoa count were noted. Testicular histological findings were evaluated. On purpose, organization of each animal was graded according to Johnsen’s scoring to assess the spermatogenesis relying on seminiferous tubule cross-section scores. Comparing to controls, FM administration caused a decrease in sperm concentration (p<0.05), an increase in total abnormal spermatozoa rates (p<0.05) and more degenerative changes in testes in mice.

Royal jelly supplementation ameliorated both sperm concentration and abnormal spermato- zoa (p<0.05) comparing to the control group. In conclusion, we suggested that royal jelly might have protective effects in the FM-induced reductions in epididymal sperm concentration and in- crease in abnormal spermatozoa rate.

Go to article

Authors and Affiliations

F. Temamoğulları
F. Aral
R. Yılmaz
Download PDF Download RIS Download Bibtex

Abstract

Starting in May 2021, green building is mandatory for new buildings in Indonesia. Greenship is a green building certification system in Indonesia issued by the Green Building Council Indonesia (GBCI) which is a member of the World GBC for the conservation and efficiency of resources (energy, water, land, materials, and nature). Greenship will be implemented in MICE which is a building for Meetings, Incentives, Conventions, and Exhibitions that has a strong economic attractiveness in Indonesia, which has a population of 270 million. Using the SEM-PLS it was quickly concluded that energy is the most influential factor in achieving platinum ratings from GBCI.With the value engineering (VE) method and life cycle cost analysis (LCC), it is needed an additional 4,689% cost for the platinum grade green costs through energy optimization will get a payback period of 3 years and 10 months. The novelty of this research, since the design, it is necessary to take steps to measure energy efficiency and other resources with a selection of materials/machines and working methods of the green concept to know the amount of additional initial costs that do not much burden investment costs compared with some future benefits of green MICE.
Go to article

Authors and Affiliations

Sutikno Sutikno
1
ORCID: ORCID
Albert Eddy Husin
1
ORCID: ORCID
Maria Magdalena Enny Yuliati
1
ORCID: ORCID

  1. Mercu Buana University, Jalan Meruya Selatan No 1 Kembangan, Jakarta Barat, Jakarta 11650, Indonesia
Download PDF Download RIS Download Bibtex

Abstract

The pathogenesis of porcine contagious pleuropneumonia is poorly understood. In the present study, a mouse model of intranasal infection by Actinobacillus pleuropneumoniae (App) was used to examine lung inflammation. The pathogical results of lung tissues showed that App-infected mice showed dyspnea and anorexia, with severe damage by acute hemorrhage, and infiltration of eosinophils and lymphocytes, as well as increased expression of caspase-1 p20, interleukin (IL)-1β, IL-6, IL-8, IL-18 and tumor necrosis factor (TNF)-α. Caspase-1 inhibitors reduced both lung tissue damage and the expression of caspase-1 p20, IL-1β, IL-6, IL-8, TNF-α and IL-18 in infected mice. These findings suggest that the caspase-1 dependent pyroptosis involved in the pathogenesis of the mouse pleuropneumonia caused by App and the inhibition of caspase-1 reduced the lung injury of this pleuropneumonia

Go to article

Authors and Affiliations

Y. Zhang
T. Yang
F. Huang
Download PDF Download RIS Download Bibtex

Abstract

This study aimed to develop an equine-derived hyperimmune serum against SARS-CoV-2 and evaluate its efficacy as a potential immunotherapy tool for the treatment of known and potential variants of COVID-19 in preclinical trials.
The novelty of this study is the whole virus and ALUM gel adjuvant formula. The horses were immunized using a whole inactivated SARS-CoV-2 antigen, and the final purified hyperimmune serum showed high plaque reduction neutralization (PRNT 50) neutralizing titers. The efficacy of the hyperimmune serum was evaluated histopathologically and biochemically in the lungs, hearts, and serum of K18 hACE2 transgenic mice (n=45), which is an accepted model organism for SARS-CoV-2 studies and was challenged with live SARS-CoV-2.
Serum treatment improved the general condition, resulting in lower levels of proinflammatory cytokines in the blood plasma, as well as reduced viral RNA titers in the lungs and hearts. Additionally, it reduced oxidative stress significantly and lessened the severity of interstitial pneumonia in the lungs when compared to infected positive controls.
The study concluded that equine-derived anti-SARS-CoV-2 antibodies could be used for COVID-19 prevention and treatment, especially in the early stages of the disease and in combination with antiviral drugs and vaccines. This treatment will benefit special patient populations such as immunocompromised individuals, as specific antibodies against SARS-CoV-2 can neutralize the virus before it enters host cells. The rapid and cost-effective production of the serum allows for its availability during the acute phase of the disease, making it a critical intervention in preventing the spread of the disease and saving lives in new variants where a vaccine is not yet developed.
Go to article

Bibliography

1. Botosso VF, Jorge SAC, Astray RM, Guimaraes AMS, Mathor MB, Carneiro PS, Durigon EL, Covas D, Oliveira DBL, Oliveira RN, Maria DA, Eto SF, Gallina NMF, Pidde G, Squaiella-Baptistão CS, Silva DT, Villas-Boas IM, Fernandes DC, Auada AVV, Banari AC, Filho AFS, Bianconi C, Utescher CLA, Oliveira DCA, Mariano DOC, Barbosa FF, Rondon G, Kapronezai J, Silva J G, Goldfeder MB, Comone P, Junior REC, Pereira TTS, Wen FH, Tambourgi DV, Chudzinski-Tavassi AM (2022) Anti-SARS-CoV-2 equine F (Ab′)2 immunoglobulin as a possible therapy for COVID-19. Sci Rep 12: 3890.
2. De Vito A, Colpani A, Saderi L, Puci M, Zauli B, Fiore V, Fois M, Meloni MC, Bitti A, Di Castri C, Maida I, Babudieri S, Sotgiu G, Madeddu G. (2022) Impact of early SARS-CoV-2 antiviral therapy on disease progression. Viruses 15: 71.
3. Dong W, Mead H, Tian L, Park JG, Garcia JI, Jaramillo S, Barr T, Kollath DS, Coyne VK, Stone NE, Jones A, Zhang J, Li A, Wang LS, Milanes-Yearsley M, Torrelles JB, Martinez-Sobrido L, Keim PS, Barker BM, Caligiuri MA, Yu J (2022) The K18-Human ACE2 transgenic mouse model recapitulates non-severe and severe COVID-19 in response to an infectious dose of the SARS-CoV-2 virus. J Virol: e0096421.
4. Golden JW, Cline CR, Zeng X, Garrison AR, Carey BD, Mucker EM, White LE, Shamblin JD, Brocato RL, Liu J, Babka AM, Rauch HB, Smith JM, Hollidge BS, Fitzpatrick C, Badger CV, Hooper JW (2020) Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI Insight 5: e142032.
5. Jha A, Barker D, Lew J, Manoharan V, Kessel JV, Haupt R, Toth D, Frieman M, Falzarano D, Kodihalli S (2022) Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection. Sci Rep 12: 16956.
6. León G, Herrera M, Vargas M, Arguedas M, Sánchez A, Segura A, Gómez A, Solano G, Aguilar E C, Risner K, Narayanan A, Bailey C, Villalta M, Hernández A, Sánchez A, Cordero D, Solano D, Durán G, Segura E, Cerdas M, Umaña D, Moscoso E, Estrada R, Gu-tiérrez J, Méndez M, Castillo AC, Sánchez L, Sánchez R, Gutiérrez JM, Díaz C, Alape A (2021) Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19. Sci Rep 11: 9825.
7. Li E, Han Q, Bi J, Wei S, Wang S, Zhang Y, Liu J, Feng N, Wang T, Wu J, Yang S, Zhao Y, Liu B, Yan F, Xia X (2023) Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection. Front Immunol 14: 1066730.
8. Luis Eduardo Cunha, Stolet AA, Strauch MA, Pereira VAR, Dumard CH, Gomes AMO, Souza PNC, Fonseca JG, Pontes FE, Meirelles LGR, Albuquerque JWM, Sacramento CQ, Rodrigues NF, Lima TM, Alvim RGF, Marsili FF, Caldeira MM, Higa LM, Monteiro FL, Zingali RB, Oliveira GAP, Souza TML, Tanuri A, Oliveira AC, Guedes H L M, Castilho L R , Silva J L (2020) Potent neutralizing equine antibodies raised against recombinant SARS-CoV-2 spike protein for COVID-19 passive immunization therapy. Cold Spring Harbor Laboratory, bioRxiv 17: 254375
9. Maccio U, Zinkernagel AS, Shambat SM, Zeng X, Cathomas G, Ruschitzka F, Schuepbach RA, Moch H, Varga Z. SARS-CoV-2 (2021) Leads to a small vessel endotheliitis in the heart. EBioMedicine 63: 103182.
10. Moreira-Soto A, Arguedas M, Brenes H, Buján W, Corrales-Aguilar E, Díaz C, Echeverri A, Flores-Díaz M, Gómez A, Hernández A, Herrera M, León G, Macaya R, Kühne A, Molina-Mora JA, Mora J, Sanabria A, Sánchez A, Sánchez L, Segura Á, Segura E, Solano D, Soto C, Stynoski JL, Vargas M, Villalta M, Reusken CBEM, Drosten C, Gutiérrez JM, Alape-Girón A, Drexler JF (2021) High efficacy of therapeutic equine hyperimmune antibodies against SARS-CoV-2 variants of concern. Frontiers in Medicine. 8: 735853.
11. Onen EA, Sonmez K, Yildirim F, Demirci EK, Gurel A (2022) Development, analysis, and preclinical evaluation of inactivated vaccine candidate for prevention of Covid-19 disease. All Life 15: 771-793.
12. Pan X, Zhou P, Fan T, Wu Y, Zhang J, Shi X, Shang W, Fang L, Jiang X, Shi J, Sun Y, Zhao S, Gong R, Chen Z, Xiao G (2020) Im-munoglobulin fragment F(ab’)2 against RBD potently neutralizes SARS-CoV-2 in vitro. Antiviral Res 182: 104868.
13. Schoell A, Heyde B, Weir D, Po-Chang C, Yiding H, Tung D (2009) Euthanasia method for mice in rapid time-course pulmonary. Pharmacokinetic Studies 48: 506.
14. Suvarna KS, Layton C, Bancroft JD (2018) Bancroft’s theory and practice of histological techniques E-Book. Elsevier health sciences, Philadelphia, pp 286-291.
15. Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, Fox JM, Chen RE, Earnest JT, Keeler SP, Ritter JH, Kang L, Dort S, Robichaud A, Head R, Holtzman MJ, Diamond MS (2020) SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol 21: 1327-1335.
16. Xu J, Xu X, Jiang L, Dua K, Hansbro PM, Liu G (2020) SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis. Respir Res 21: 182.
17. Yu P, Deng W, Bao L, Qu Y, Xu Y, Zhao W, Han Y, Qin C (2022) Comparative pathology of the nasal epithelium in K18-hACE2 Tg mice, hACE2 Tg mice, and hamsters infected with SARS-CoV-2. Vet Pathol 59: 602-612.
18. Zhang Q, Wang Y, Qi C, Shen L, Li J (2020) Clinical trial analysis of 2019-nCoV therapy registered in China. J Med Virol 92: 540-545.

Go to article

Authors and Affiliations

E.A. Onen
1
E.K. Demirci
2

  1. Kocak Pharmaceutical Company, Biotechnology and Vaccine R&D, Tekirdag, Turkey
  2. Histology and Embryology Department, Istanbul Faculty of Medicine,Istanbul University, Istanbul, Turkey

This page uses 'cookies'. Learn more